The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

C. J. Sweeney, Kathy Miller, S. E. Sissons, S. Nozaki, D. K. Heilman, J. Shen, Jr Sledge G.W.

Research output: Contribution to journalArticle

303 Citations (Scopus)

Abstract

Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examined the antiangiogenic activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited angiogenesis in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the antiangiogenic properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the antiangiogenic agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the antiangiogenic effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.

Original languageEnglish
Pages (from-to)3369-3372
Number of pages4
JournalCancer Research
Volume61
Issue number8
StatePublished - Apr 15 2001

Fingerprint

docetaxel
Endothelial Growth Factors
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Endothelial Cells
Fibroblast Growth Factor 2
Cell Proliferation
Angiogenesis Inhibitors
Cell Movement
2-methoxyestradiol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. / Sweeney, C. J.; Miller, Kathy; Sissons, S. E.; Nozaki, S.; Heilman, D. K.; Shen, J.; Sledge G.W., Jr.

In: Cancer Research, Vol. 61, No. 8, 15.04.2001, p. 3369-3372.

Research output: Contribution to journalArticle

@article{765c543d08aa4f1ab09065dcb8e3ddb2,
title = "The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors",
abstract = "Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examined the antiangiogenic activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited angiogenesis in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the antiangiogenic properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the antiangiogenic agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the antiangiogenic effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.",
author = "Sweeney, {C. J.} and Kathy Miller and Sissons, {S. E.} and S. Nozaki and Heilman, {D. K.} and J. Shen and {Sledge G.W.}, Jr",
year = "2001",
month = "4",
day = "15",
language = "English",
volume = "61",
pages = "3369--3372",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors

AU - Sweeney, C. J.

AU - Miller, Kathy

AU - Sissons, S. E.

AU - Nozaki, S.

AU - Heilman, D. K.

AU - Shen, J.

AU - Sledge G.W., Jr

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examined the antiangiogenic activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited angiogenesis in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the antiangiogenic properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the antiangiogenic agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the antiangiogenic effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.

AB - Numerous chemotherapeutic agents have been shown to have an inhibitory effect on endothelial cell proliferation and migration, and tubule formation. In this study, we examined the antiangiogenic activity of docetaxel. Docetaxel inhibited endothelial cell proliferation and tubule formation in vitro in a dose-dependent fashion. Docetaxel treatment also inhibited angiogenesis in an in vivo Matrigel plug assay. The endothelial stimulating factors, vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor are able to protect endothelial cells from the antiangiogenic properties of docetaxel. This protective effect can be overcome by a recombinant humanized monoclonal antibody directed against VEGF in both in vitro and in vivo models. Similarly, combination of docetaxel with the antiangiogenic agent 2-methoxyestradiol also overcomes the protective effect of VEGF in both in vitro and in vivo models. These data suggest that microenvironmental factors (e.g., local release of VEGF and basic fibroblast growth factor) could play a role in decreasing the antiangiogenic effects of docetaxel, whereas agents such as 2-methoxyestradiol and recombinant humanized monoclonal antibody directed against VEGF may reverse this protective effect.

UR - http://www.scopus.com/inward/record.url?scp=0035870297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035870297&partnerID=8YFLogxK

M3 - Article

C2 - 11309294

AN - SCOPUS:0035870297

VL - 61

SP - 3369

EP - 3372

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -